Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Non-Current Assets (2011 - 2026)

Lite Strategy (LITS) posted Non-Current Assets of $46.8 million for Q1 2026, down 35.0% on a QoQ basis from $72.0 million in Q4 2025.

Analysis

Lite Strategy (LITS) Non-Current Assets (2011 - 2026) Analysis & Trends

Lite Strategy has reported Non-Current Assets for 16 years, with the latest figure at $46.8 million in Q1 2026.

  • On a quarterly basis, Non-Current Assets changed N/A year-over-year to $46.8 million in Q1 2026; TTM through Mar 2026 was $218.9 million, a 35733.06% increase from a year earlier, with the FY2024 full-year figure at $606000.0, down 95.44% from the prior year.
  • Non-Current Assets was $46.8 million for Q1 2026 at Lite Strategy, down from $72.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $100.1 million in Q3 2025, with the low at $5000.0 in Q3 2024.
  • Average Non-Current Assets over 5 years is $23.9 million, with a median of $13.1 million recorded in 2023.
  • The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 99.96% in 2024, then jumped 2001920.0% in 2025.
  • Over 5 years, Non-Current Assets stood at $14.2 million in 2022, then slipped by 12.63% to $12.4 million in 2023, then plunged by 99.96% to $5000.0 in 2024, then surged by 1440400.0% to $72.0 million in 2025, then plunged by 35.0% to $46.8 million in 2026.
  • The last three Non-Current Assets figures came in at $46.8 million (Q1 2026), $72.0 million (Q4 2025), and $100.1 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 1.96 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 564.41 Mn
10 Lite Strategy 38.03 Mn 30.49 Mn - 46.81 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 46.81 Mn
Dec 31, 2025 72.03 Mn
Sep 30, 2025 100.10 Mn
Sep 30, 2024 5,000.00
Jun 30, 2024 606,000.00
Mar 31, 2024 11.89 Mn
Dec 31, 2023 12.37 Mn
Sep 30, 2023 12.83 Mn
Jun 30, 2023 13.28 Mn
Mar 31, 2023 13.70 Mn
Dec 31, 2022 14.15 Mn
Sep 30, 2022 14.68 Mn
Jun 30, 2022 10.71 Mn
Mar 31, 2022 10.96 Mn
Dec 31, 2021 8.74 Mn
Sep 30, 2021 8.99 Mn
Jun 30, 2021 9.28 Mn
Mar 31, 2021 9.56 Mn
Dec 31, 2020 9.85 Mn
Sep 30, 2020 10.08 Mn